Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company ...

Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with ...

According to the Alzheimer's Association, the potential lifetime impact is 1 in 3. Gail Youngdale is one of them. "My mother ...

Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. | All told, third-quarter U.S. Leqembi sales grew 33% over the prior quarter to $39 ...

We continue to see momentum with ongoing product launches and we are increasingly excited about the potential of our pipeline ...

Biogen Inc. is now projecting a better-than-expected 2024 as the company continues to see an uptick in sales from Leqembi, ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug ...

Even though Biogen raised earnings guidance, the company still has “some potentially concerning signals” in its base business ...

The stock is down 29 percent this year as of Tuesday’s close, largely due to a sluggish start for Leqembi — on the market to treat Alzheimer’s since January 2023 — and the recent rejection ...